Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia (25)

2024

  1. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  2. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  3. Guidelines for inhaled sedation in the ICU

    Revista Espanola de Anestesiologia y Reanimacion, Vol. 71, Núm. 2, pp. 90-111

  4. High PEEP with recruitment maneuvers versus Low PEEP During General Anesthesia for Surgery -a Bayesian individual patient data meta-analysis of three randomized clinical trials

    Anesthesiology

  5. Safety and outcome of children, adolescents and young adults participating in phase I/II clinical oncology trials: a 9-year center experience

    Frontiers in Pediatrics, Vol. 12

  6. Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry

    Haematologica

2023

  1. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

    Blood Cancer Journal, Vol. 13, Núm. 1

  2. Consensus document on palliative care in cardiorenal patients

    Frontiers in Cardiovascular Medicine, Vol. 10

  3. Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus

    Journal of gynecologic oncology, Vol. 34, Núm. 5, pp. e57

2022

  1. Combining MRI and clinical data to detect high relapse risk after the first episode of psychosis

    Schizophrenia, Vol. 8, Núm. 1

  2. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

    Cancers, Vol. 14, Núm. 23

  3. The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure

    Clinical Kidney Journal, Vol. 15, Núm. 5, pp. 865-872

2021

  1. Corrigendum to “Corrigendum to Hydroxyethyl starch and acute kidney injury in high-risk patients undergoing cardiac surgery: A prospective multicenter study” [J Clin Anesth 2021 Oct;73:110367] (Journal of Clinical Anesthesia (2021) 73, (S0952818021002063), (10.1016/j.jclinane.2021.110367))

    Journal of Clinical Anesthesia

  2. Frequency of five cardiovascular/hemostatic entities as primary manifestations of SARS-CoV-2 infection: Results of the UMC-19-S2

    International Journal of Cardiology, Vol. 330, pp. 268-272

  3. Hydroxyethyl starch and acute kidney injury in high-risk patients undergoing cardiac surgery: A prospective multicenter study

    Journal of Clinical Anesthesia, Vol. 73

2020

  1. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  2. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2019

  1. Marcaje de leucocitos con 99mTc-exametazima y policitemia vera: un hallazgo casual

    Ars pharmaceutica, Vol. 60, Núm. 4, pp. 227-230

  2. MicroRNA 7 impairs insulin signaling and regulates Aβ levels through posttranscriptional regulation of the insulin receptor substrate 2, insulin receptor, insulin-degrading enzyme, and liver X receptor pathway

    Molecular and Cellular Biology, Vol. 39, Núm. 22

  3. The altered transcriptome and DNA methylation profiles of docetaxel resistance in breast cancer PDX models

    Molecular Cancer Research, Vol. 17, Núm. 10, pp. 2063-2076